Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
NDC API
0
VMF
0
FDF
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1-propanesulfonamide, N-(cis-3-(methyl-7h-pyrrolo(2,3-d)pyrimidin-4-ylamino)cyclobutyl)-
2. Abrocitinib
3. N-(cis-3-(methyl(7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-1-propanesulfonamide
4. N-(cis-3-(methyl(7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide
5. Pf-04965842
1. Abrocitinib
2. 1622902-68-4
3. Pf-04965842
4. Cibinqo
5. Abrocitinib [usan]
6. 73sm5sf3or
7. Chembl4101725
8. N-[3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide
9. N-{cis-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide
10. 1-propanesulfonamide, N-(cis-3-(methyl-7h-pyrrolo(2,3-d)pyrimidin-4-ylamino)cyclobutyl)-
11. N-(3-(methyl(7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide, Cis-
12. N-(cis-3-(methyl(7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide
13. N-[cis-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)cyclobutyl]-1-propanesulfonamide
14. Unii-73sm5sf3or
15. D7d
16. N-((1s,3s)-3-(methyl(7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide
17. N-((1s,3s)-3-(methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide
18. Abrocitinib [inn]
19. Abrocitinib [jan]
20. Abrocitinib (jan/usan)
21. Abrocitinib [who-dd]
22. Gtpl9991
23. Chembl3655081
24. Schembl15970412
25. Schembl15970413
26. Pf-04965842(abrocitinib)
27. Bdbm159748
28. Dtxsid301126581
29. Pf-04965842 (abrocitinib)
30. Bcp30441
31. Ex-a3037
32. Xpc90268
33. Ac8575
34. Bdbm50243847
35. Mfcd30187577
36. S8765
37. Zb1566
38. Zinc261115849
39. Db14973
40. Sb18849
41. Compound 25 [pmid: 29298069]
42. Ncgc00601823-02
43. Ac-36318
44. As-84437
45. Sy248874
46. Hy-107429
47. Cs-0028460
48. Pf04965842
49. D11400
50. Us9035074, 2
51. A936574
52. Pf-04965842, >=98% (hplc)
53. Pf-04965842pf-04965842
54. Pf-04965842; Pf 04965842; Pf04965842
55. N-(cis-3-(methyl(7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-1-propanesulfonamide
56. N-(cis-3-(methyl(7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide
57. Abrocitinib;n-[cis-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)cyclobutyl]-1-propanesulfonamide
Molecular Weight | 323.42 g/mol |
---|---|
Molecular Formula | C14H21N5O2S |
XLogP3 | 1.7 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 6 |
Exact Mass | 323.14159610 g/mol |
Monoisotopic Mass | 323.14159610 g/mol |
Topological Polar Surface Area | 99.4 Ų |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 474 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
D11AH
D - Dermatologicals
D11 - Other dermatological preparations
D11A - Other dermatological preparations
D11AH - Agents for dermatitis, excluding corticosteroids
D11AH08 - Abrocitinib
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?